Atlas Trials

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Clinical trial NCT01177813 · COMPLETED

Trial details

NCT number
NCT01177813
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2010-07-01
Primary completion
2012-03-01
Enrollment
986

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.